Stage III Non-small-cell Lung Cancer Clinical Trial
Official title:
Phase II Trial of Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer
Elderly (age 70 years or older) or >18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open label study of concurrent, split course chemoradiation followed by Durvalumab (MEDI4736).
The rationale for the study is to identify another cohort of stage III NSCLC for whom adjuvant Durvalumab can be safely given, expanding its utilization and benefits. With a unique, extremely well-tolerated 4-phase split course CRT regimen preceding the administration of Durvalumab, we expect to be able to offer adjuvant Durvalumab to a significant proportion of patients on study. Patients who have completed four cycles of chemoradiation (Radiation is 60 Gy in 30 fractions administered over 12 weeks with 1-1.5 week breaks between cycles; Chemotherapy is once every 3 weeks for up to 4 cycles) will go on to receive durvalumab (MEDI4736) monotherapy as 1500mg durvalumab (MEDI4736) via IV infusion Q4W for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48 until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. Primary objectives are: 1. To determine the percentage of poor risk and/or elderly unresectable stage III NSCLC patients who complete split course chemoradiation 2. To determine the safety and tolerability of durvalumab (MEDI4736) after completion of chemoradiation in this group of patients. Secondary Objectives are: 1. To determine the 1-year overall survival rate 2. To determine the 1-year progression-free survival rate 3. To determine the 1-year loco-regional progression-free survival rate 4. To determine rate of grade 3 and 4 toxicities with this regimen in the selected patient population ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04085250 -
Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
|
Phase 2 | |
| Recruiting |
NCT03742687 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
N/A | |
| Completed |
NCT01733589 -
Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04325763 -
A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
|
Phase 3 | |
| Active, not recruiting |
NCT03589547 -
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
|
Phase 2 | |
| Not yet recruiting |
NCT04304638 -
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
|
||
| Active, not recruiting |
NCT01576796 -
Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04181372 -
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03871153 -
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT05331833 -
Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.
|